Osteonecrosis Treatment Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Drugs and Surgeries), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
The osteonecrosis treatment market size is expected to grow from US$ 0.637 billion in 2022 to US$ 1.021 billion by 2030; the market is estimated to register a CAGR of 6.08% from 2022 to 2030.
Key factors driving the market growth include the rising cases of osteonecrosis in people owing to an increasing number of road accidents and long-term use of steroids among patients. Additionally, the rising geriatric population and growing awareness about bone health benefit the osteonecrosis treatment market. However, the high cost associated with surgical treatments and the risk factors associated with treatment drugs hamper the osteonecrosis treatment market.
Osteonecrosis, also known as avascular necrosis (AVN), is a painful bone disease that results in the death of bone cells. It happens when blood flow to bones is disrupted and worsens over time. The causes of this condition include broken bones, dislocated hips, radiation therapy, and alcohol abuse.
Rising Cases of Orthopedic Injuries and Increasing Geriatric Population Drive Osteonecrosis Treatment Market Growth
According to statistics published by Clevelandclinic.org in 2021, 10,000–20,000 Americans are diagnosed with avascular necrosis (AVN) annually, with the condition affecting individuals of all ages and genders. Nearly 20% of people who experience hip dislocation develop AVN. The cases of osteonecrosis are rising globally owing to the increasing number of bone and joint injuries caused by fatal accidents. Although osteonecrosis more commonly affects the hip, it can also hamper the condition of the humerus, knee, and talus. As per an article published by StatPearls in 2023, AVN causes 10% of hip arthroplasties in the US, mostly in people aged 30–65. A displaced hip or knee might cut off blood supply to the leg. As a result, the tissues in the leg may not receive enough blood (a condition known as ischemia) and may die (a condition known as necrosis). Elbow or upper arm fractures can occasionally impede blood flow to the forearm, creating similar complications. When blood supply to a bone is interrupted, a portion of the bone may die, causing osteonecrosis. As per the article published by PubMed Central in January 2022, a cohort study included 170,934 major trauma patients. The study concluded that 78.0% of the major trauma patients with traumatic hip dislocations were injured in road traffic accidents, particularly in motor vehicle accidents (49.9%).
Older people are more likely to experience osteonecrosis as they are more prone to bone degeneration and fractures. In an article published by PubMed in 2020, a study was carried out to assess the effectiveness of cannulated internal fixation in long-term outcomes in 73 patients with femoral neck fracture (FNF), alongside identifying the risk factors affecting outcomes. The study results showed that 7 (i.e., ~10%) experienced femoral head necrosis, and 4 underwent hip replacement. According to the World Health Organization (WHO), 1 in 6 people worldwide will be aged 60 years or over by 2030, with an estimated 1.4 billion people over 60. Therefore, the burgeoning geriatric population and growing awareness about bone health favor the osteonecrosis treatment market.
Market Opportunity
Development of Biomechanical Solutions and Ongoing Clinical Trials to Launch New Innovations Are Creating Opportunities in the Market.
Biomechanical techniques for avascular necrosis therapy attempt to solve joint mechanics and functioning concerns. AVN frequently causes structural changes in bone, particularly in weight-bearing joints, resulting in discomfort and decreased mobility. Biomechanical solutions are vital in preserving joint function, reducing pain, and improving a patient’s quality of life. These approaches often involve a multidisciplinary collaboration between orthopedic surgeons, biomechanical engineers, and rehabilitation specialists to provide comprehensive care. Various biomechanical approaches are currently being studied and utilized as a treatment for AVN. These approaches include developing specialized and customizable implants for patient-specific treatments and biomechanical analysis using advanced imaging to understand altered patient biomechanics. For instance, in an article published by Sage Journals in January 2023, a study was carried out to stop the advancement of avascular necrosis by restoring lunate vascularity in nine patients who were treated with vascularized bone grafts and interim radiocarpal spanning internal fixation. The study concluded that utilizing a local vascularized bone graft with temporary internal radiocarpal spanning fixation provides a therapeutic option with the advantages of internal immobilization.
Similarly, in an article published by Scielo Brazil in June 2023, a cross-sectional study included nine patients diagnosed with osteonecrosis of the femoral head. The study used Vicon Motion Capture Systems for patients' gait analysis. The study found that individuals with osteonecrosis of the femoral head adopt compensatory gait mechanisms to protect their hip joints. These mechanisms include increased pelvic motion and decreased knee flexion. The study also identified decreased moments for hip flexion and adduction, which may be related to muscle weakness in these groups. Therefore, biomechanical analysis is useful for evaluating the functionality of patients with AVN. This allows physicians to assess daily activities that can significantly affect patients' quality of life. Additionally, it helps them invest in immediate non-operative measures that can improve pain and functionality, eventually leading to better surgical outcomes.
Moreover, according to the European Union Clinical Trials Register, 7255 clinical trials were conducted with subjects under 18 years old, and data on older pediatric trials. According to an article published on MDPI in March 2023, an open-label, non-randomized, prospective clinical trial was conducted to evaluate the efficacy of mesenchymal stem cells (MSCs) in treating idiopathic osteonecrosis of the femoral head (ONFH) in patients with stage less than IIC in the ARCO classification. Eight patients were included in the trial. Autologous bone marrow (40 mL) was obtained four weeks before therapy, and MSCs were expanded under Good Manufacturing Practice (GMP) standards. The study concluded that using autologous mesenchymal stem cells (MSCs) is a safe and potentially effective treatment option for patients with femoral head osteonecrosis (ONFH).
SEGMENTAL OVERVIEW
The “Global Osteonecrosis Treatment Market” is segmented based on treatment type, end user, and geography. Based on product type, the market is bifurcated into drugs and surgeries. Drug segments are further segmented into NSAIDs, blood thinners, cholesterol-lowering drugs, and others. Similarly, the surgeries segment is sub-segmented into total joint replacement/ total hip arthroplasty (THA), core decompression surgery, bone graft, osteotomy, etc. The drugs segment held the largest market share in 2022. However, the surgeries segment is anticipated to grow with the highest CAGR of 7.6%.
In terms of end users, the osteonecrosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others. The hospital segment is expected to record the highest CAGR in the market from 2022 to 2030. Osteonecrosis treatment involves complicated surgeries that need special medical attention, including diagnosis, treatment, and continuous monitoring. Hospitals play an essential role in delivering complete healthcare services to osteonecrosis patients. Depending on the disease's stage and severity, they provide various treatment options for osteonecrosis. Conservative techniques such as pain management, physical therapy, and lifestyle changes may be included in these treatments. Furthermore, surgical therapies such as joint-preserving operations or joint replacement surgeries may be undertaken in severe cases.
Key factors driving the market growth include the rising cases of osteonecrosis in people owing to an increasing number of road accidents and long-term use of steroids among patients. Additionally, the rising geriatric population and growing awareness about bone health benefit the osteonecrosis treatment market. However, the high cost associated with surgical treatments and the risk factors associated with treatment drugs hamper the osteonecrosis treatment market.
Osteonecrosis, also known as avascular necrosis (AVN), is a painful bone disease that results in the death of bone cells. It happens when blood flow to bones is disrupted and worsens over time. The causes of this condition include broken bones, dislocated hips, radiation therapy, and alcohol abuse.
Rising Cases of Orthopedic Injuries and Increasing Geriatric Population Drive Osteonecrosis Treatment Market Growth
According to statistics published by Clevelandclinic.org in 2021, 10,000–20,000 Americans are diagnosed with avascular necrosis (AVN) annually, with the condition affecting individuals of all ages and genders. Nearly 20% of people who experience hip dislocation develop AVN. The cases of osteonecrosis are rising globally owing to the increasing number of bone and joint injuries caused by fatal accidents. Although osteonecrosis more commonly affects the hip, it can also hamper the condition of the humerus, knee, and talus. As per an article published by StatPearls in 2023, AVN causes 10% of hip arthroplasties in the US, mostly in people aged 30–65. A displaced hip or knee might cut off blood supply to the leg. As a result, the tissues in the leg may not receive enough blood (a condition known as ischemia) and may die (a condition known as necrosis). Elbow or upper arm fractures can occasionally impede blood flow to the forearm, creating similar complications. When blood supply to a bone is interrupted, a portion of the bone may die, causing osteonecrosis. As per the article published by PubMed Central in January 2022, a cohort study included 170,934 major trauma patients. The study concluded that 78.0% of the major trauma patients with traumatic hip dislocations were injured in road traffic accidents, particularly in motor vehicle accidents (49.9%).
Older people are more likely to experience osteonecrosis as they are more prone to bone degeneration and fractures. In an article published by PubMed in 2020, a study was carried out to assess the effectiveness of cannulated internal fixation in long-term outcomes in 73 patients with femoral neck fracture (FNF), alongside identifying the risk factors affecting outcomes. The study results showed that 7 (i.e., ~10%) experienced femoral head necrosis, and 4 underwent hip replacement. According to the World Health Organization (WHO), 1 in 6 people worldwide will be aged 60 years or over by 2030, with an estimated 1.4 billion people over 60. Therefore, the burgeoning geriatric population and growing awareness about bone health favor the osteonecrosis treatment market.
Market Opportunity
Development of Biomechanical Solutions and Ongoing Clinical Trials to Launch New Innovations Are Creating Opportunities in the Market.
Biomechanical techniques for avascular necrosis therapy attempt to solve joint mechanics and functioning concerns. AVN frequently causes structural changes in bone, particularly in weight-bearing joints, resulting in discomfort and decreased mobility. Biomechanical solutions are vital in preserving joint function, reducing pain, and improving a patient’s quality of life. These approaches often involve a multidisciplinary collaboration between orthopedic surgeons, biomechanical engineers, and rehabilitation specialists to provide comprehensive care. Various biomechanical approaches are currently being studied and utilized as a treatment for AVN. These approaches include developing specialized and customizable implants for patient-specific treatments and biomechanical analysis using advanced imaging to understand altered patient biomechanics. For instance, in an article published by Sage Journals in January 2023, a study was carried out to stop the advancement of avascular necrosis by restoring lunate vascularity in nine patients who were treated with vascularized bone grafts and interim radiocarpal spanning internal fixation. The study concluded that utilizing a local vascularized bone graft with temporary internal radiocarpal spanning fixation provides a therapeutic option with the advantages of internal immobilization.
Similarly, in an article published by Scielo Brazil in June 2023, a cross-sectional study included nine patients diagnosed with osteonecrosis of the femoral head. The study used Vicon Motion Capture Systems for patients' gait analysis. The study found that individuals with osteonecrosis of the femoral head adopt compensatory gait mechanisms to protect their hip joints. These mechanisms include increased pelvic motion and decreased knee flexion. The study also identified decreased moments for hip flexion and adduction, which may be related to muscle weakness in these groups. Therefore, biomechanical analysis is useful for evaluating the functionality of patients with AVN. This allows physicians to assess daily activities that can significantly affect patients' quality of life. Additionally, it helps them invest in immediate non-operative measures that can improve pain and functionality, eventually leading to better surgical outcomes.
Moreover, according to the European Union Clinical Trials Register, 7255 clinical trials were conducted with subjects under 18 years old, and data on older pediatric trials. According to an article published on MDPI in March 2023, an open-label, non-randomized, prospective clinical trial was conducted to evaluate the efficacy of mesenchymal stem cells (MSCs) in treating idiopathic osteonecrosis of the femoral head (ONFH) in patients with stage less than IIC in the ARCO classification. Eight patients were included in the trial. Autologous bone marrow (40 mL) was obtained four weeks before therapy, and MSCs were expanded under Good Manufacturing Practice (GMP) standards. The study concluded that using autologous mesenchymal stem cells (MSCs) is a safe and potentially effective treatment option for patients with femoral head osteonecrosis (ONFH).
SEGMENTAL OVERVIEW
The “Global Osteonecrosis Treatment Market” is segmented based on treatment type, end user, and geography. Based on product type, the market is bifurcated into drugs and surgeries. Drug segments are further segmented into NSAIDs, blood thinners, cholesterol-lowering drugs, and others. Similarly, the surgeries segment is sub-segmented into total joint replacement/ total hip arthroplasty (THA), core decompression surgery, bone graft, osteotomy, etc. The drugs segment held the largest market share in 2022. However, the surgeries segment is anticipated to grow with the highest CAGR of 7.6%.
In terms of end users, the osteonecrosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others. The hospital segment is expected to record the highest CAGR in the market from 2022 to 2030. Osteonecrosis treatment involves complicated surgeries that need special medical attention, including diagnosis, treatment, and continuous monitoring. Hospitals play an essential role in delivering complete healthcare services to osteonecrosis patients. Depending on the disease's stage and severity, they provide various treatment options for osteonecrosis. Conservative techniques such as pain management, physical therapy, and lifestyle changes may be included in these treatments. Furthermore, surgical therapies such as joint-preserving operations or joint replacement surgeries may be undertaken in severe cases.
1. INTRODUCTION
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. RESEARCH METHODOLOGY
4. OSTEONECROSIS TREATMENT MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. OSTEONECROSIS TREATMENT MARKET - KEY MARKET DYNAMICS
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. OSTEONECROSIS TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1 Osteonecrosis Treatment - Global Market Overview
6.2 Osteonecrosis Treatment - Global Market and Forecast to 2030
7. OSTEONECROSIS TREATMENT MARKET – REVENUE ANALYSIS (USD MILLION) – BY TREATMENT TYPE, 2020-2030
7.1 Overview
7.2 Drugs
7.2.1 Nonsteroidal Anti-Inflammatory Drugs
7.2.2 Blood Thinners
7.2.3 Cholesterol-Lowering Drugs
7.2.4 Others
7.3 Surgery
7.3.1 Core Decompression Surgery
7.3.2 Osteotomy
7.3.3 Bone Graft
7.3.4 Total joint replacement
7.3.5 Others
8. OSTEONECROSIS TREATMENT MARKET – REVENUE ANALYSIS (USD MILLION) – BY END USER, 2020-2030
8.1 Overview
8.2 Hospitals
8.3 Specialty Clinics
8.4 Ambulatory Surgical Centers
8.5 Others
9. OSTEONECROSIS TREATMENT MARKET -REVENUE ANALYSIS (USD MILLION), 2020-2030 – GEOGRAPHICAL ANALYSIS
9.1 North America
9.1.1 North America Osteonecrosis Treatment Market Overview
9.1.2 North America Osteonecrosis Treatment Market Revenue and Forecasts to 2030
9.1.3 North America Osteonecrosis Treatment Market Revenue and Forecasts and Analysis - By Treatment Type
9.1.4 North America Osteonecrosis Treatment Market Revenue and Forecasts and Analysis - By End User
9.1.5 North America Osteonecrosis Treatment Market Revenue and Forecasts and Analysis - By Countries
9.1.5.1 United States Osteonecrosis Treatment Market
9.1.5.1.1 United States Osteonecrosis Treatment Market, by Treatment Type
9.1.5.1.2 United States Osteonecrosis Treatment Market, by End User
9.1.5.2 Canada Osteonecrosis Treatment Market
9.1.5.2.1 Canada Osteonecrosis Treatment Market, by Treatment Type
9.1.5.2.2 Canada Osteonecrosis Treatment Market, by End User
9.1.5.3 Mexico Osteonecrosis Treatment Market
9.1.5.3.1 Mexico Osteonecrosis Treatment Market, by Treatment Type
9.1.5.3.2 Mexico Osteonecrosis Treatment Market, by End User
Note - Similar analysis would be provided for below mentioned regions/countries
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 Spain
9.2.5 United Kingdom
9.2.6 Rest of Europe
9.3 Asia-Pacific
9.3.1 Australia
9.3.2 China
9.3.3 India
9.3.4 Japan
9.3.5 South Korea
9.3.6 Rest of Asia-Pacific
9.4 Middle East and Africa
9.4.1 South Africa
9.4.2 Saudi Arabia
9.4.3 U.A.E
9.4.4 Rest of Middle East and Africa
9.5 South and Central America
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Rest of South and Central America
11. INDUSTRY LANDSCAPE
11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments
12. COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration
13. OSTEONECROSIS TREATMENT MARKET - KEY COMPANY PROFILES
13.1 Novartis AG
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
Note - Similar information would be provided for below list of companies
13.2 Teva Pharmaceutical Industries Ltd.
13.3 Zimmer Biomet
13.4 Pfizer Inc
13.5 Stryker
13.6 Exactech Inc
13.7 Merck Co Inc
13.8 Dr Reddy’s Laboratories Ltd.
13.9 Viatris Inc
13.10 Horizon Therapeutics plc
14. APPENDIX
14.1 Glossary
14.2 About The Insight Partners
14.3 Market Intelligence Cloud
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. RESEARCH METHODOLOGY
4. OSTEONECROSIS TREATMENT MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. OSTEONECROSIS TREATMENT MARKET - KEY MARKET DYNAMICS
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. OSTEONECROSIS TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1 Osteonecrosis Treatment - Global Market Overview
6.2 Osteonecrosis Treatment - Global Market and Forecast to 2030
7. OSTEONECROSIS TREATMENT MARKET – REVENUE ANALYSIS (USD MILLION) – BY TREATMENT TYPE, 2020-2030
7.1 Overview
7.2 Drugs
7.2.1 Nonsteroidal Anti-Inflammatory Drugs
7.2.2 Blood Thinners
7.2.3 Cholesterol-Lowering Drugs
7.2.4 Others
7.3 Surgery
7.3.1 Core Decompression Surgery
7.3.2 Osteotomy
7.3.3 Bone Graft
7.3.4 Total joint replacement
7.3.5 Others
8. OSTEONECROSIS TREATMENT MARKET – REVENUE ANALYSIS (USD MILLION) – BY END USER, 2020-2030
8.1 Overview
8.2 Hospitals
8.3 Specialty Clinics
8.4 Ambulatory Surgical Centers
8.5 Others
9. OSTEONECROSIS TREATMENT MARKET -REVENUE ANALYSIS (USD MILLION), 2020-2030 – GEOGRAPHICAL ANALYSIS
9.1 North America
9.1.1 North America Osteonecrosis Treatment Market Overview
9.1.2 North America Osteonecrosis Treatment Market Revenue and Forecasts to 2030
9.1.3 North America Osteonecrosis Treatment Market Revenue and Forecasts and Analysis - By Treatment Type
9.1.4 North America Osteonecrosis Treatment Market Revenue and Forecasts and Analysis - By End User
9.1.5 North America Osteonecrosis Treatment Market Revenue and Forecasts and Analysis - By Countries
9.1.5.1 United States Osteonecrosis Treatment Market
9.1.5.1.1 United States Osteonecrosis Treatment Market, by Treatment Type
9.1.5.1.2 United States Osteonecrosis Treatment Market, by End User
9.1.5.2 Canada Osteonecrosis Treatment Market
9.1.5.2.1 Canada Osteonecrosis Treatment Market, by Treatment Type
9.1.5.2.2 Canada Osteonecrosis Treatment Market, by End User
9.1.5.3 Mexico Osteonecrosis Treatment Market
9.1.5.3.1 Mexico Osteonecrosis Treatment Market, by Treatment Type
9.1.5.3.2 Mexico Osteonecrosis Treatment Market, by End User
Note - Similar analysis would be provided for below mentioned regions/countries
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 Spain
9.2.5 United Kingdom
9.2.6 Rest of Europe
9.3 Asia-Pacific
9.3.1 Australia
9.3.2 China
9.3.3 India
9.3.4 Japan
9.3.5 South Korea
9.3.6 Rest of Asia-Pacific
9.4 Middle East and Africa
9.4.1 South Africa
9.4.2 Saudi Arabia
9.4.3 U.A.E
9.4.4 Rest of Middle East and Africa
9.5 South and Central America
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Rest of South and Central America
11. INDUSTRY LANDSCAPE
11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments
12. COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration
13. OSTEONECROSIS TREATMENT MARKET - KEY COMPANY PROFILES
13.1 Novartis AG
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
Note - Similar information would be provided for below list of companies
13.2 Teva Pharmaceutical Industries Ltd.
13.3 Zimmer Biomet
13.4 Pfizer Inc
13.5 Stryker
13.6 Exactech Inc
13.7 Merck Co Inc
13.8 Dr Reddy’s Laboratories Ltd.
13.9 Viatris Inc
13.10 Horizon Therapeutics plc
14. APPENDIX
14.1 Glossary
14.2 About The Insight Partners
14.3 Market Intelligence Cloud
